Loading…
Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study
Please cite this paper as: Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, Therasakvichya S, Hamontri S, Linasmita V, Bunyapipat S, Chindavijak S, Ittiwisavakul K, Khemapech N, Suekwattana P, Thanapprapasr D, Lumbiganon P. Depot medroxyprogesterone acetate and e...
Saved in:
Published in: | BJOG : an international journal of obstetrics and gynaecology 2012-05, Vol.119 (6), p.672-677 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Please cite this paper as: Wilailak S, Vipupinyo C, Suraseranivong V, Chotivanich K, Kietpeerakool C, Tanapat Y, Therasakvichya S, Hamontri S, Linasmita V, Bunyapipat S, Chindavijak S, Ittiwisavakul K, Khemapech N, Suekwattana P, Thanapprapasr D, Lumbiganon P. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case–control study. BJOG 2012;119:672–677.
Objective To evaluate the effect of depot medroxyprogesterone acetate (DMPA) in protecting against epithelial ovarian cancer (EOC) and to evaluate factors associated with the risk of EOC.
Design A multicentre, case–control study.
Setting Twelve hospitals located across Thailand.
Population Three hundred and thirty patients with EOC (‘cases’) and 982 matched controls were recruited from the 12 hospitals. Cases were newly diagnosed patients with EOC, demonstrated pathologically. Controls were age‐matched patients admitted to different wards in the same hospital.
Methods Cases and controls were interviewed by trained interviewers using a standardised pre‐tested questionnaire. The factors associated with EOC were evaluated using univariate and multivariate analyses.
Main outcome measures The odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relationship between DMPA and EOC.
Results The use of DMPA was found to be associated with a 39% reduction in the risk of EOC with an OR of 0.61 and a 95% CI of 0.44–0.85 (P = 0.002). A significant risk reduction (83%) was observed when the duration of DMPA use was >3 years (OR 0.17; 95% CI 0.07–0.39; P |
---|---|
ISSN: | 1470-0328 1471-0528 |
DOI: | 10.1111/j.1471-0528.2012.03298.x |